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Abstract:  
Background: Sickle cell anaemia is a congenital hemolytic disorder caused by mutation in the β-
globin gene at position 6 with replacement of glutamic acid by valine. Patients who are 
homozygous for this mutation suffer from hemolytic anaemia and other serious complications. The 
underlying pathology of much of these complications is the occurrence of recurrent vasoocclusion 
due to microthrombi formation resulting in organs ischaemia.  
Methods: In this study we investigated the role of vWF as a determinant of sickle cell disease 
severity through its contribution to the formation of such microthrombi. The clinical disease 
severity was determined using two different scoring methods, and vWF antigen level in the plasma 
was estimated by using ELISA technique. 
Results and discussion: Seventy Sudanese patients were investigated in this study. They were 35 
females and 35 males, the mean of their ages± standard deviation was 6.8 ± 4.7 years. Seventeen 
controls with normal haemoglobin were also included with mean age of 6.5 years. Thirty four 
patients presented during vasoocclusive crisis and 36 presented in steady state.  
vWF was high (179.83%)  among patients compared to controls (82.4%), p< 0.001. there was 
positive correlation between severity score and vWF level in the plasma in steady state in the two 
scoring methods used ( r = 0.79, p = 0.008 for method I and r = 0.78, p = 0.009 for method II). So, 
Severity of sickle cell disease increases with elevation of vWF level in the plasma in the steady 
state. 
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ickle cell disease (SCD) is an inherited 
autosomal recessive disorder of the β-
globin gene caused by mutation in 
position 6 with replacement of glutamate by 
valine. The disease is characterized by 
haemolytic anaemia, intermittent episodes of 
vascular occlusions that can cause both acute 
and chronic pain, increased susceptibility to 
infections and end organ damage1. There are 
several factors affecting the clinical severity 
of the disease which is extremely variable2-4. 
The frequency of painful crises is considered 
to be the major indicator of disease severity5. 
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The pathophysiology of vaso-occlusive 
episodes is complex, involving not only 
polymerization of the mutant haemoglobin, 
but also interaction between sickled red blood 
cells, endothelium, platelets, leukocytes and 
plasma constituents6. 
Thromboembolic phenomenon is a well 
known feature of SCD with evidence of in 
vivo thrombin generation, endothelial 
activation and increased activation of 
coagulation and hence depletion of 
anticoagulants both in steady state and during 
vaso-occlusive crisis7-9. There is also 
activation of cellular elements including white 
cells and platelets10-12. 
As von Willebrand factor (vWF) plays an 
important role in platelet aggregation and 
thrombus formation13 this study aimed to find 
a possible role for vWF in determining the 
clinical disease severity in patients with sickle 
cell disease. 
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Patients and Methods 
This study was conducted at the sickle cell 
anaemia clinic at Khartoum Children's 
Emergency Hospital (KCEH) in Sudan. 
Seventy patients with homozygous sickle cell 
hemoglobin attending the clinic and 17 
healthy controls were enrolled in the study 
after informed verbal consent of the patients 
or guardians of patients. All patients were 
known cases and haemoglobin electrophoresis 
was done previously. Patients who received 
blood transfusion less than 6 weeks before the 
time of sampling were excluded. A 
questionnaire addressing personal and socio-
demographic data of the patients as well as 
history of conditions which determine the 
severity of the disease was used. Patients 
were grouped into those presenting during 
vaso-occlusive crisis and those presenting in 
steady state. The vaso-occlusive episode was 
defined as pain in the arms, legs, back, 
abdomen, chest or head that lasted at least two 
hours necessitating seeking medical care and 
analgesia.14 All patients were subjected to 
physical examination. Two scoring methods 
for grading of disease severity were used; the 
first method (scoring method I) used by Ketty 
and colleagues3 with a modification by 
omission of fundal examination. The second 
scoring method (scoring method II) considers 
the number of painful crisis per year (pain 
rate) irrespective of hospital admissions and 
administration of narcotics.5  
Five ml of venous blood were obtained from 
each patient and control. Prothrombin time 
(PT) and activated partial thromboplastin time 
(APTT) were performed on citrated platelet 
poor plasma. The rest of the plasma was 
stored at –20ºC to be used later for the 
determination of von Willebrand factor levels. 
Basic haematological parameters were 
obtained by an automated cell counter 
(Sysmex Kx-21, Japan). Haemogobin 
concentration in g/L (Hb), total white blood 
cell counts (TWBC x 109 /L) and platelet 
counts (x 109 /L) were measured using 
standard methods. Measurement of plasma 
vWF was performed by enzyme linked 
immunosorbant assay (ELISA). This is a 
sandwich ELISA using Asserachrom vWF kit  
 
(Diagnostica, Stago, France). The analysis 
was done following the manufacturer's 
instructions. 
Statistical analysis 
Data were analyzed by computer software 
statistical package for social science (SPSS) 
program. Pearson correlation, chi square test, 
t-test and one-way analysis of variance were 
used to compare the associated levels. P value 
< 0.05 was considered significant. 
Results 
Fifty percent of the patients were females. 
The ages ranged between 9 months and 17 
years. The mean age± standard deviation was 
6.8 ± 4.7 years with the age group 1-5 years 
comprising 35.7%. 
 Of the control group 47.06% were females. 
The ages ranged between 8 months and 16 
years.  
Thirty six patients (51.4%) had zero score 
when we used the scoring method I indicating 
mild form of the disease, 22.8% (n= 16) had 
score one, which indicated a moderate form of 
the disease, while 25.7% (n =18) scored 2 or 
more, which indicated a more severe form of 
the disease. Using the pain rate i.e. scoring 
method II as an indicator of disease severity, 
23 patients (32.8%) had severe disease and 
the rest 67.1% (n= 47) had a mild disease.  
The mean haemoglobin level among the 
patients was 71.1g/L, with most of the 
patients having a level ranging between 50 - 
100g/L. The platelet counts ranged between 
94-1025×109/ L indicating the presence of 
thrombocytopenia (5.7%) and thrombocytosis 
(41.4%) (Table1). 
 
Table 1Platelet count (x109/L) distribution 
among the patients       
          
Platelet count X 109/L N0 (%) 
Less than 150  4 (5.7) 
150-400 37 (52.9) 
More than 400  29 (41.4) 
Total  70 (100) 
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The lower platelet counts were present mainly 
in patients presenting during vaso-occlusive 
crisis. 
The control mean of vWF was 82.4% and the 
mean of the patient levels was 179.83%. 
Ninety-nine percent of the study group had 
vWF antigen level above that of the control 
mean. The difference between the means of 
the patients and controls was highly 
significant (P<0.001). Painful episodes were 
accompanied by the highest levels of vWF, 
and steady state with the lowest level. 
However, the difference was not statistically 
significant (P= 0.479). 
Correlation between severity score and vWF 
levels in steady state revealed a strong direct 
correlation in both of the scoring methods 




Fig. 1. Correlation between vWF mean (%) and severity score (method I) in steady state sickle 




vWF mean (%) 
Fig. 2. Correlation between vWF mean (%) and total number of painful episodes per year 
(Method II) in steady state sickle cell disease, r =0.78, p = 0.009. 
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There was also a direct correlation between 
clinical disease severity and TWBC when 
using scoring method II (P=0.017), but not 
when using scoring methodI. There was no 
correlation between clinical disease severity 
and haemoglobin levels in neither of the 
scoring methods. Low platelet counts were 
associated with the lowest vWF levels, 
normal counts with the highest levels and 
thrombocytosis with intermediate levels. 
There was significantly prolonged APTT 
among patients presenting with painful crises 
(P=0.012) while the patients presenting with 
fever had significantly shorter APTT 
(P=0.018). APTT was directly correlated with 
vWF but inversely correlated with platelet 
counts (p< 0.001 for both). Prothrombin time 
(PT) was within normal range in the whole 
population of patients. 
 
Discussion 
Our results showed that patients with sickle 
cell anaemia had significantly (P<0.001) 
higher levels of vWF in the plasma compared 
to the controls and is in agreement with 
previous studies7,15. vWF mean levels during 
crises though higher than that of the steady 
state, did not show statistical significance   
(p= 0.479). There was a direct correlation 
between severity score and vWF level in the 
plasma in steady state in the two scoring 
methods used (Fig. 1 and 2). This correlation 
of vWF with the severity of sickle cell 
anaemia can be attributed to the fact thatt 
vWF is an acute phase protein and its level in 
the plasma can be elevated in a number of 
clinical situations specially those affecting the 
blood vessels. vWF is released in plasma due 
to the inflammatory process induced by the 
adhesion of sickled red blood cells to the 
endothelium leading to narrowing of the 
vessel lumen creating high sheer effect16. 
Adhesion of platelets to the adherent sickled 
cells and their activation will release more 
vWF. It has been previously reported that the 
level of vWF in the plasma is directly 
correlated with the extent of adhesion of 
sickled red blood cells to the endothelium 
which had been found to be correlated with 
the severity of the disease2,17. A considerable 
number of our patients had high platelet 
counts (41.4%) particularly in steady state, in 
keeping with the results of Leslie et al 18,19 
which would increase the interaction between 
the platelet receptors and vWF leading to 
enhancement of thrombus formation20. 
Another fact that can explain this correlation 
between the high vWF level and the disease 
severity is the direct correlation between 
factor VIII and vWF21. High levels of factor 
VIII during steady state of sickle cell anaemia 
were reported earlier7,18,22. Richardson 
reported also elevated vWF together with the 
elevation of factor VIII7. However, the author 
did not correlate the levels to each other. This 
elevated level of factor VIII with activation of 
platelets will put patients with sickle cell 
anaemia on a procoagulant state. Patients with 
vaso-occlusive crisis had shown significantly 
faster APTT (p = 0.018) which is an indicator 
of coagulation activation23. The sequences of 
events in sickle cell anaemia can be 
summarized as follows: in steady state there is 
thrombocytosis, normal APTT and vWF level 
at its lowest level but still higher than that of 
the controls. Early in crisis there is activation 
of platelets and coagulation leading to 
shortening of APTT. On progressing of the 
crisis, activation of the platelets becomes 
maximum and associated with elevation of 
vWF in the plasma. Later on in the crisis there 
is consumption of platelets and coagulation 
factors in the microthrombi formation 
resulting both in platelet count reduction and 
APTT prolongation. Reduction of the platelet 
count is associated with reduced release of 
vWF from α-granules and therefore, vWF 
levels go down gradually to the steady state 
level.  
 
Elevated plasma vWF levels and high shear 
rate created by adherence of sickled 
erythrocytes to the endothelium will lead to 
accelerated platelet activation and aggregation 
and also a higher rate of thrombin generation. 
These conditions will consequently lead to 
fibrin and microthrombi formation leading to 
vaso-occlusion and organ ischaemia. 
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In conclusion high levels of vWF in the 
plasma of patients with sickle cell anaemia in 
steady state are associated with severe clinical 
disease. 
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